LT2373691T - Anti-fxi antikūnai ir jų panaudojimo būdai - Google Patents

Anti-fxi antikūnai ir jų panaudojimo būdai

Info

Publication number
LT2373691T
LT2373691T LTEP09837993.6T LT09837993T LT2373691T LT 2373691 T LT2373691 T LT 2373691T LT 09837993 T LT09837993 T LT 09837993T LT 2373691 T LT2373691 T LT 2373691T
Authority
LT
Lithuania
Prior art keywords
methods
fxi antibodies
fxi
antibodies
Prior art date
Application number
LTEP09837993.6T
Other languages
English (en)
Inventor
Andras Gruber
Erik TUCKER
David Gailani
Original Assignee
Oregon Health & Science University
Vanderbilt University
Andras Gruber
Tucker, Erik I.
David Gailani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, Vanderbilt University, Andras Gruber, Tucker, Erik I., David Gailani filed Critical Oregon Health & Science University
Publication of LT2373691T publication Critical patent/LT2373691T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
LTEP09837993.6T 2008-12-18 2009-12-18 Anti-fxi antikūnai ir jų panaudojimo būdai LT2373691T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18
PCT/US2009/068768 WO2010080623A2 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use

Publications (1)

Publication Number Publication Date
LT2373691T true LT2373691T (lt) 2019-05-27

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09837993.6T LT2373691T (lt) 2008-12-18 2009-12-18 Anti-fxi antikūnai ir jų panaudojimo būdai

Country Status (15)

Country Link
US (3) US8388959B2 (lt)
EP (1) EP2373691B1 (lt)
AU (1) AU2009335643B2 (lt)
CA (1) CA2747519C (lt)
CY (1) CY1121562T1 (lt)
DK (1) DK2373691T3 (lt)
ES (1) ES2720594T3 (lt)
HR (1) HRP20190605T1 (lt)
HU (1) HUE042940T2 (lt)
LT (1) LT2373691T (lt)
PL (1) PL2373691T3 (lt)
PT (1) PT2373691T (lt)
SI (1) SI2373691T1 (lt)
TR (1) TR201904662T4 (lt)
WO (1) WO2010080623A2 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
TR201904662T4 (tr) * 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
WO2016109774A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
AR107505A1 (es) * 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
CA3018124A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
GEP20227382B (en) * 2016-06-14 2022-05-25 Merck Sharp & Dohme Anti-coagulation factor xi antibodies
PE20191319A1 (es) * 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
IL267538B1 (en) * 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
CN111902427A (zh) 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
AU2018436195A1 (en) * 2018-08-09 2021-02-18 Shanghai Benemae Pharmaceutical Corporation Anti-factor XI antibodies
KR20210118853A (ko) * 2019-01-21 2021-10-01 아로노라 인크. 항혈전과 항염 효과를 갖는 인자 xi에 대한 신규 인간화 항체 및 그 용도
CN113474374A (zh) 2019-04-16 2021-10-01 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CA3184718A1 (en) * 2020-07-02 2022-01-06 Lei Wang Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4177275A1 (en) 2020-07-03 2023-05-10 Suzhou Alphamab Co., Ltd Coagulation factor xi (fxi) binding protein
US20230131338A1 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
PL3002298T3 (pl) * 2007-11-21 2020-03-31 Oregon Health & Science University Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania
ES2702365T3 (es) 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
JP5501369B2 (ja) 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
TR201904662T4 (tr) * 2008-12-18 2019-05-21 Gruber Andras Anti-fxı antikorları ve kullanma yöntemleri.
UA107112C2 (en) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Activator of soluble guanylate cyclase
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012152629A1 (de) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituierte imidazopyridine und imidazopyridazine und ihre verwendung
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
AP2014007541A0 (en) 2011-09-02 2014-03-31 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
WO2013167669A1 (en) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Also Published As

Publication number Publication date
HRP20190605T1 (hr) 2019-05-31
AU2009335643B2 (en) 2014-05-29
ES2720594T3 (es) 2019-07-23
US8388959B2 (en) 2013-03-05
DK2373691T3 (en) 2019-04-15
WO2010080623A2 (en) 2010-07-15
EP2373691A2 (en) 2011-10-12
WO2010080623A3 (en) 2010-11-18
CA2747519C (en) 2019-04-02
US20150093395A1 (en) 2015-04-02
US8940883B2 (en) 2015-01-27
CY1121562T1 (el) 2020-05-29
HUE042940T2 (hu) 2019-07-29
PL2373691T3 (pl) 2019-07-31
EP2373691A4 (en) 2012-10-31
US20110250207A1 (en) 2011-10-13
US9637550B2 (en) 2017-05-02
US20130129745A1 (en) 2013-05-23
CA2747519A1 (en) 2010-07-15
PT2373691T (pt) 2019-05-08
AU2009335643A1 (en) 2011-07-07
TR201904662T4 (tr) 2019-05-21
EP2373691B1 (en) 2019-01-23
SI2373691T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
IL248723A0 (en) Specific antibodies against the bcr complex and methods of using them
PT2373691T (pt) Anticorpos anti-fxi e métodos de utilização
IL250624A0 (en) Anti-fgfr3 antibodies and methods of using them
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
ZA201005351B (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EG27167A (en) Microemulsifiers and methods of making and using same
HK1171236A1 (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use fcrh5
IL215795A0 (en) Anti-il-17f antibodies and methods of use thereof
EP2347038A4 (en) METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (en) Compounds and methods of use
ZA201107128B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
HK1149933A1 (en) Diazacarbazoles and methods of use
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL209548A0 (en) Diazacarbazoles and methods of use
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
IL219136A0 (en) Anti-hepsin antibodies and methods using same